Systematic review / meta-analysis / 2022
GLP-1 receptor agonist use was linked to increased risks of gallbladder and biliary diseases in a meta-analysis of randomized clinical trials.
A systematic review and meta-analysis of 76 RCTs with 103,371 patients examined the risk of gallbladder or biliary diseases associated with GLP-1 receptor agonists compared to placebo or non-GLP-1 RA drugs. Randomization to GLP-1 RA treatment was associated with increased risk of gallbladder or biliary diseases (RR 1.37; 95% CI, 1.23-1.52), including cholelithiasis (RR 1.27; 95% CI, 1.10-1.47), cholecystitis (RR 1.36; 95% CI, 1.14-1.62), and biliary disease (RR 1.55; 95% CI, 1.08-2.22). Risks were higher in trials for weight loss (RR 2.29; 95% CI, 1.64-3.18) than for type 2 diabetes or other diseases (RR 1.27; 95% CI, 1.14-1.43), as well as with higher doses (RR 1.56 vs 0.99 for lower doses) and longer durations of use (RR 1.40 vs 0.79 for shorter duration).
- Study type
- Systematic review and meta-analysis of randomized clinical trials
- Who was studied
- 103,371 adult patients across 76 RCTs (mean age 57.8 years; 40.5% women)
- What was measured
- Composite of gallbladder or biliary diseases, biliary diseases, biliary cancer, cholecystectomy, cholecystitis, and cholelithiasis
THE PAPER
Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
He L, Wang J, Ping F, Yang N, Huang J, Li Y, Xu L, Li W, Zhang H. JAMA Intern Med, 2022.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.